Literature DB >> 25947545

Predictors of long-term survival in patients with stage IV colorectal cancer with multi-organ metastases: a single-center retrospective analysis.

Yuji Miyamoto1, Naoko Hayashi2, Yasuo Sakamoto3, Mayuko Ohuchi3, Ryuma Tokunagam3, Junji Kurashige3, Yukiharu Hiyoshi3, Yoshifumi Baba3, Shiro Iwagami3, Naoya Yoshida3, Megumi Yoshida3, Hideo Baba4.   

Abstract

BACKGROUND: The prognosis for most patients with stage IV colorectal cancer (CRC) and multi-organ metastases is poor. However, little information is currently available on prognostic factors in these patients. The aim of this study was to identify predictors of a good prognosis in this patient group.
METHODS: This was a single-center retrospective study in which we examined the relationship between patient characteristics and prognosis in 161 stage IV CRC patients with indications for first-line systemic chemotherapy. Cox proportional-hazards models were used to compute hazard ratios (HR) for death, adjusted for clinical and pathological characteristics.
RESULTS: Of the 161 patients recruited to the study, 83 had single-organ and 78 had multi-organ metastases. Median survival time was significantly shorter in patients with multi-organ metastases than in those with single-organ metastases (19.2 vs. 42.0 months, respectively; log-rank, P < 0.001). There was no significant difference in survival between patients with metastases in two versus three or more organs (log-rank; P = 0.368). According to univariate analysis, primary tumor sites in the left side of the colon and in the rectum, a pretreatment carcinoembryonic antigen concentration of >50 ng/mL, a well-/moderately differentiated tumor, and R0 resection of metastatic lesions were associated with better overall survival. According to multivariate analysis, left-sided location of the primary tumor [HR 0.414, 95 % confidence interval (CI) 0.216-0.815; P = 0.011] and R0 resection of metastatic lesions (HR 0.247, 95 % CI 0.04 0-0.834; P = 0.021) were independently associated with good prognosis.
CONCLUSIONS: Our results indicate that the site of the primary tumor in the left side of the colon and in the rectum and R0 resection of metastatic lesions are predictors of a good prognosis in patients with stage IV CRC and multi-organ metastases.

Entities:  

Keywords:  Colorectal cancer; Multi-organ metastasis; Prognostic factor; Stage IV

Mesh:

Substances:

Year:  2015        PMID: 25947545     DOI: 10.1007/s10147-015-0835-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  20 in total

1.  How aggressive should we be in patients with stage IV colorectal cancer?

Authors:  Li-Jen Kuo; Shuh-Yan Leu; Mei-Ching Liu; James Jer-Min Jian; Skye Hongiun Cheng; Chung-Ming Chen
Journal:  Dis Colon Rectum       Date:  2003-12       Impact factor: 4.585

2.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2011-10-15       Impact factor: 3.402

3.  Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data.

Authors:  Jennifer M Weiss; Patrick R Pfau; Erin S O'Connor; Jonathan King; Noelle LoConte; Gregory Kennedy; Maureen A Smith
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

4.  Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?

Authors:  Timothy J Price; Carol Beeke; Shahid Ullah; Robert Padbury; Guy Maddern; David Roder; Amanda R Townsend; James Moore; Amitesh Roy; Yoko Tomita; Christos Karapetis
Journal:  Cancer       Date:  2014-11-06       Impact factor: 6.860

5.  Prognostic impact of tumor location in stage IV colon cancer: a propensity score analysis in a multicenter study.

Authors:  Soichiro Ishihara; Takeshi Nishikawa; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Keisuke Hata; Hioaki Nozawa; Takamitsu Kanazawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Yojiro Hashiguchi; Kenichi Sugihara; Toshiaki Watanabe
Journal:  Int J Surg       Date:  2014-08-01       Impact factor: 6.071

6.  The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status.

Authors:  Hae Ran Yun; Woo Yong Lee; Won Suk Lee; One Suk Lee; Yong Beom Cho; Seong Hyeon Yun; Ho-Kyung Chun
Journal:  Int J Colorectal Dis       Date:  2007-05-08       Impact factor: 2.571

7.  Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients.

Authors:  Leyo Ruo; Christina Gougoutas; Philip B Paty; Jose G Guillem; Alfred M Cohen; W Douglas Wong
Journal:  J Am Coll Surg       Date:  2003-05       Impact factor: 6.113

8.  Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma.

Authors:  S Murata; Y Moriya; T Akasu; S Fujita; K Sugihara
Journal:  Cancer       Date:  1998-09-15       Impact factor: 6.860

Review 9.  Are there two sides to colorectal cancer?

Authors:  Barry Iacopetta
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

10.  Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.

Authors:  J M Bae; J H Kim; N-Y Cho; T-Y Kim; G H Kang
Journal:  Br J Cancer       Date:  2013-07-30       Impact factor: 7.640

View more
  12 in total

1.  Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer.

Authors:  Emily K Elizabeth McCracken; Gregory P Samsa; Deborah A Fisher; Norma E Farrow; Karenia Landa; Kevin N Shah; Dan G Blazer; Sabino Zani
Journal:  HPB (Oxford)       Date:  2019-05-30       Impact factor: 3.647

2.  Postoperative chemotherapy is associated with prognosis of stage IV colorectal cancer treated with preoperative chemotherapy/chemoradiotherapy and curative resection.

Authors:  Hiroaki Nozawa; Hirofumi Sonoda; Hiroaki Ishii; Shigenobu Emoto; Koji Murono; Manabu Kaneko; Kazuhito Sasaki; Takeshi Nishikawa; Yasutaka Shuno; Toshiaki Tanaka; Kazushige Kawai; Keisuke Hata; Soichiro Ishihara
Journal:  Int J Colorectal Dis       Date:  2019-12-05       Impact factor: 2.571

Review 3.  The Significance of Neutrophil Extracellular Traps in Colorectal Cancer and Beyond: From Bench to Bedside.

Authors:  Dingchang Li; Jiakang Shao; Bo Cao; Ruiyang Zhao; Hanghang Li; Wenxing Gao; Peng Chen; Lujia Jin; Li Cao; Shuaifei Ji; Guanglong Dong
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

4.  2D-DIGE-MS Proteomics Approaches for Identification of Gelsolin and Peroxiredoxin 4 with Lymph Node Metastasis in Colorectal Cancer.

Authors:  Cheng-Yi Huang; Ko-Chao Lee; Shui-Yi Tung; Wen-Shin Huang; Chih-Chuan Teng; Kam-Fai Lee; Meng-Chiao Hsieh; Hsing-Chun Kuo
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

5.  DNA methylation-regulated and tumor-suppressive roles of miR-487b in colorectal cancer via targeting MYC, SUZ12, and KRAS.

Authors:  Xu Chen; Zhi-Feng Lin; Wen-Jin Xi; Wei Wang; Dan Zhang; Fan Yang; Yu-Fang Li; Yi Huo; Tian-Ze Zhang; Yi-Hong Jiang; Wei-Wei Qin; An-Gang Yang; Tao Wang
Journal:  Cancer Med       Date:  2019-02-21       Impact factor: 4.452

6.  Efficacy and safety of nivolumab for metastatic biliary tract cancer.

Authors:  Miaomiao Gou; Yong Zhang; Haiyan Si; Guanghai Dai
Journal:  Onco Targets Ther       Date:  2019-01-25       Impact factor: 4.147

7.  Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study.

Authors:  Antonino Grassadonia; Pietro Di Marino; Corrado Ficorella; Alessio Cortellini; Katia Cannita; Alessandro Parisi; Teresa Gamucci; Federica Zoratto; Patrizia Vici; Maddalena Barba; Ettore Porreca; Matteo Neri; Angelo Veronese; Clara Natoli; Michele De Tursi; Nicola Tinari
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

Review 8.  The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC).

Authors:  Debasish Basak; Mohammad Nasir Uddin; Jake Hancock
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

9.  Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.

Authors:  Sophia C Kamran; Jeffrey W Clark; Hui Zheng; Darrell R Borger; Lawrence S Blaszkowsky; Jill N Allen; Eunice L Kwak; Jennifer Y Wo; Aparna R Parikh; Ryan D Nipp; Janet E Murphy; Lipika Goyal; Andrew X Zhu; A John Iafrate; Ryan B Corcoran; David P Ryan; Theodore S Hong
Journal:  Cancer Med       Date:  2018-05-17       Impact factor: 4.452

Review 10.  Colorectal Cancer Biomarkers in the Era of Personalized Medicine.

Authors:  Jai N Patel; Mei Ka Fong; Megan Jagosky
Journal:  J Pers Med       Date:  2019-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.